Genscript Biotech (SEHK:1548) Could Be 46% Above Fair Value As Lilly TuneLab Deal Lands

Simply Wall St.10-01

AdvertisementGenscript Biotech joins Lilly’s AI drug discovery network Genscript Biotech (SEHK:1548) has agreed to join Lilly TuneLab, supplying preferred-rate wet lab services that turn AI-generated ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2672793757?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041","is_english":true,"pubTime":"2026-10-01 18:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2672793757","market":"sg","top_or_hot":-1,"title":"Genscript Biotech (SEHK:1548) Could Be 46% Above Fair Value As Lilly TuneLab Deal Lands","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementGenscript Biotech joins Lilly’s AI drug discovery network Genscript Biotech (SEHK:1548) has agreed to join Lilly TuneLab, supplying preferred-rate wet lab services that turn AI-generated ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1548/genscript-biotech-shares/news/genscript-biotech-sehk1548-could-be-46-above-fair-value-as-l\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genscript Biotech (SEHK:1548) Could Be 46% Above Fair Value As Lilly TuneLab Deal Lands</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenscript Biotech (SEHK:1548) Could Be 46% Above Fair Value As Lilly TuneLab Deal Lands\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-01 18:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1548/genscript-biotech-shares/news/genscript-biotech-sehk1548-could-be-46-above-fair-value-as-l><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementGenscript Biotech joins Lilly’s AI drug discovery network Genscript Biotech (SEHK:1548) has agreed to join Lilly TuneLab, supplying preferred-rate wet lab services that turn AI-generated ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1548/genscript-biotech-shares/news/genscript-biotech-sehk1548-could-be-46-above-fair-value-as-l\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGIX","symbol_name":"通用人工智能 ETF-AGIX","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1548/genscript-biotech-shares/news/genscript-biotech-sehk1548-could-be-46-above-fair-value-as-l","article_id":"2672793757","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1548/genscript-biotech-shares/news/genscript-biotech-sehk1548-could-be-46-above-fair-value-as-l","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2672793757","pubTimestamp":1790849571,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Genscript Biotech joins Lilly’s AI drug discovery network\nGenscript Biotech (SEHK:1548) has agreed to join Lilly TuneLab, supplying preferred-rate wet lab services that turn AI-generated drug discovery predictions into experimental data for member companies on the platform.\nThe latest Lilly TuneLab agreement comes after a sharp share price run, with Genscript Biotech posting a 1-month share price return of 32.41% and a 90-day share price return of 241.14%, while the 1-year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGIX":"通用人工智能 ETF-AGIX","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","01548":"金斯瑞生物科技","QTOC":"Innovator Growth Accelerated Plus ETF - October","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK4581":"高盛持仓","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","XBI":"SPDR S&P Biotech ETF","ARTY":"ISHARES FUTURE AI & TECH ETF","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","AIPO":"Defiance AI and Power Infrastructure ETF","BK4585":"ETF&股票定投概念","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK1583":"高瓴概念","VTHR":"Vanguard Russell 3000 ETF","BK4588":"碎股"},"translate_title":"随着礼来 TuneLab 交易达成，金斯瑞生物科技 (SEHK:1548) 可能比公允价值高出 46%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIX":0.65,"VTHR":0.65,"AIPO":0.65,"ARTY":0.65,"CHAT":0.65,"01548":0.9,"QTOC":0.65,"XBI":1.5},"content_text":"AdvertisementGenscript Biotech joins Lilly’s AI drug discovery network Genscript Biotech (SEHK:1548) has agreed to join Lilly TuneLab, supplying preferred-rate wet lab services that turn AI-generated drug discovery predictions into experimental data for member companies on the platform. The latest Lilly TuneLab agreement comes after a sharp share price run, with Genscript Biotech posting a 1-month share price return of 32.41% and a 90-day share price return of 241.14%, while the 1-year total shareholder return sits at 168.30%. Scan beyond Genscript Biotech and see which other AI-driven drug development players are gaining momentum with our hand-picked 133 healthcare AI stocks. A share price that has more than tripled in 90 days now trades above both analyst targets and one estimate of fair value. Is the market overreacting to Genscript Biotech’s AI and DNA platforms, or is it still underpricing them? Most Popular Narrative: 46% Overvalued Genscript Biotech last closed at HK$44.86, while the most followed narrative pegs fair value at HK$30.66. This implies the share price sits well above that estimate and places a lot of weight on the AI story and new equity capital.  The CARVYKTI launch by Legend Biotech (GenScript's major subsidiary) is exceeding industry expectations, with operational breakeven and group-level profitability targeted by 2026, which is likely to drive higher equity income and improve GenScript's net margins and overall earnings trajectory.  See why 3 investors see Genscript Biotech as 46% overvalued. Result: Fair Value of HK$30.66 (OVERVALUED) Still, the Genscript Biotech story can shift quickly if rising competition squeezes margins or if heavy R&D and capacity spending fails to translate into commercial payoff. Find out about the key risks to this Genscript Biotech narrative. Next Steps If this Genscript Biotech story feels pulled between excitement and caution, that is because it is. Act while sentiment is fresh, and weigh both sides by checking the 1 key reward and 1 important warning sign. Looking for more Genscript Biotech style investment ideas? If Genscript Biotech has your attention, do not stop at a single opportunity. Use targeted stock lists to pressure test your thesis and spot alternatives early.  Chase value with discipline by focusing on companies that combine quality fundamentals with compressed valuations using the 190 high quality undervalued stocks. Prioritise staying power by concentrating on businesses with cleaner finances and sturdier balance sheets through the list of solid balance sheet and fundamentals (205 results). Hunt for tomorrow's potential standouts by scanning financially strong but less-followed opportunities using the 617 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2672793757","isCrawlerRequest":true}